VEGF antibody (C-Term)

Catalog No. ABIN6242881

This anti-VEGF antibody is a Rabbit Polyclonal antibody detecting VEGF in WB and IHC (p). Suitable for Human.

Quick Overview for VEGF antibody (C-Term) (ABIN6242881)

Target: VEGF (Vascular Endothelial Growth Factor (VEGF))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This VEGF antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB11705

Product Details anti-VEGF Antibody

Binding Specificity: C-Term

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This VEGF antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human VEGF Antibody.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:2000. WB: 1:2000. IHC-P: 1:10~50

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

Target Details for VEGF

Target: VEGF (Vascular Endothelial Growth Factor (VEGF))

Alternative Name: VEGF

Background: Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Angiogenesis accounts for the formation of vasculature into previously avascular organs such as brain and kidney. Angiogenic activity in the adult is required during the normal tissue repair, and for the remodeling of the female reproductive organs (ovulation and placental development). Certain pathological conditions, such as tumor growth and diabetic retinopathy, also require angiogenesis. Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor. VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1), VEGFR-2 (flk-1/KDR), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo. VEGF is a heparin-binding glycoprotein that is secreted as a homodimer of 45 kDa.

Molecular Weight: 27042

NCBI Accession: NP_001020537, NP_001020538, NP_001020539, NP_001020540, NP_001020541, NP_001028928, NP_001165093, NP_001165094, NP_001165095, NP_001165096, NP_001165097, NP_001165098, NP_001165099, NP_00

UniProt: P15692